Broad Genomic Profiling Reveals Cancer Type–Specific Molecular Alterations with Potential Prognostic and Translational Relevance in Hepatobiliary and Pancreatic Cancers
This retrospective study of 309 hepatobiliary and pancreatic cancers demonstrates that broad genomic profiling using the ACT Onco+® panel identifies frequent, cancer type-specific alterations in genes not covered by standard panels, some of which show significant associations with postoperative recurrence and potential translational relevance.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Cancer is not a single disease but a collection of hundreds of distinct conditions, each driven by unique errors in the body's genetic code. In recent years, scientists have developed a method called comprehensive genomic profiling, which acts like a high-resolution scan of a tumor's DNA. This technology reads hundreds of genes at once to find the specific mutations that caused the cancer to grow. For doctors, this is a powerful tool because it can sometimes reveal a target for a drug that fits that specific genetic error, turning a one-size-fits-all treatment into a personalized strategy. However, for cancers of the liver, bile ducts, and pancreas, this approach has hit a wall. While some patients have clear genetic targets, many do not, leaving doctors with few options. The question remains: are we missing important clues because our genetic scans are not looking at enough genes?
A team of researchers in Japan set out to answer this by examining the genetic makeup of 309 patients who had surgery for cancers of the liver, bile ducts, or pancreas. They used a broad testing panel that reads 440 cancer-related genes, a much wider net than the standard clinical tests currently available in many hospitals, which typically look at fewer than 350 genes. The goal was not just to find known targets, but to see if this expanded view revealed new patterns that could help predict how the disease would behave or point toward future treatments. The researchers analyzed tissue samples that had been carefully stored after the patients' surgeries, ensuring they were looking at the actual genetic material of the tumors.
The results showed that looking at more genes provided a significantly clearer picture. Across the 309 patients, the team identified nearly 4,500 genetic changes. On average, each patient had 13 distinct alterations in their tumor DNA. As expected, the study confirmed that different types of these cancers have their own signature genetic profiles. For instance, tumors in the liver often carried changes in a gene called CTNNB1, while bile duct cancers frequently showed alterations in TP53, and pancreatic cancers were dominated by changes in KRAS. These patterns matched what scientists already knew. However, the broader scan also uncovered a different layer of information. Five of the ten most frequently altered genes in the entire group were not included in the standard clinical panels used today. These genes, which include MUC16, SYNE1, and USH2A, appeared across multiple types of liver and pancreatic cancers, suggesting they are common features of these diseases that current tests routinely miss.
The researchers then asked if these newly discovered, frequently altered genes held any clues about a patient's future. They focused on five of the most common genes found only in their broader test. In patients with liver cancer, those whose tumors had changes in a gene called FAT1 experienced a return of their disease much sooner after surgery than those without the change. Conversely, in patients with neuroendocrine tumors—a specific type of cancer that arises from hormone-producing cells—those with changes in a gene called USH2A did not experience any recurrence after surgery during the follow-up period. While these findings are preliminary and require further study to confirm, they suggest that these overlooked genes might serve as early warning signs for how aggressive a tumor is likely to be.
The study also looked at whether these new genetic findings could lead to new treatments. The team searched for ongoing clinical trials that were testing drugs targeting the pathways associated with these genes. They found that researchers are already developing therapies for some of these targets, such as drugs that interact with the Hippo signaling pathway, which is linked to the FAT1 gene, or immunotherapies aimed at MUC16. However, the authors were careful to note that these connections are currently just hypotheses. None of these treatments have yet been proven to work specifically for the patients in this study, and the genes themselves are not yet established as reliable guides for choosing therapy.
Ultimately, this research demonstrates that expanding the scope of genetic testing reveals a richer landscape of molecular details in liver and pancreatic cancers. By casting a wider net, scientists can identify frequent genetic changes that standard tests miss, some of which appear to be linked to how quickly a cancer returns after treatment. While these findings do not immediately change how doctors treat patients today, they provide a roadmap for future discovery. The study suggests that the key to better outcomes for these difficult cancers may lie in understanding the full genetic story, not just the most obvious chapters.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.